Lansoprazole (pronounced /lænˈsoʊprəzoʊl/, lan-SOE-pra-zole, INN) is a proton-pump inhibitor (PPI) which prevents the stomach from producing gastric acid. It is manufactured by a number of companies worldwide under several brand names (some brand names include: Prevacid, Helicid, Zoton, Inhibitol). It was first approved by the U.S. Food and Drug Administration (FDA) in 1995.[1]
Prevacid patent protection expired on November 10, 2009.[2] As of November 12, 2009 (2009 -11-12)[update] lansoprazole is available over-the-counter (OTC) in the U.S. in a 15 mg dose marketed by Novartis as Prevacid 24HR.[3][4][5]
Currently (November 19, 2009), prescription Lansoprazole and OTC Prevacid sell for about 85% and 25% of the cost of prescription Prevacid, respectively, in the U.S.
Pharmacology
Lansoprazole is a proton-pump inhibitor (PPI) in the same pharmacologic class as omeprazole. Lansoprazole has been marketed for many years and is one of several PPIs available.[6] An isomer of lansoprazole is dexlansoprazole (Kapidex).[7]
Lansoprazole's plasma elimination half-life is not proportional to the duration of the drug's effects (i.e. gastric acid suppression). The mean plasma elimination half-life is 1.5 hours,[8] and the effects of the drug last for over 24 hours after it has been used for 1 day or more.[9]
Indications
Lansoprazole is indicated for:
Drug Interactions
Side effects
- Infrequent: dry mouth, insomnia, drowsiness, blurred vision, rash, pruritus
- Rarely and very rarely: taste disturbance, liver dysfunction, peripheral oedema, hypersensitivity reactions (including bronchospasm, urinary, angioedema, anaphylaxis), photosensitivity, fever, sweating, depression, interstitial nephritis, blood disorders (including leukopenia, leukocytosis, pancytopenia, thrombocytopenia), arthralgia, myalgia, skin reactions (including Stevens-Johnson syndrome, toxic epidermal necrolysis, bullous eruption)
- Severe: Gastro-intestinal disturbances (such as nausea 1.3%, abdominal pain 2.1%, diarrhea 3.8%).[8]
Proton-pump inhibitors may be associated with a greater risk of hip fractures,[11] clostridium difficile-associated diarrhea.[12] Patients are frequently administered the drugs in intensive care as a protective measure against ulcers, but this use is also associated with a 30% increase in occurrence of pneumonia.[13]
Brand names
The drug is sold under several brand names, including:[1]
- Agopton (Germany)
- Aprazol (Turkey)
- Digest (Indonesia)
- Duogast (Syria)
- Lanpro (India)
- Lanzol (India)
- Lanzul (Slovenia)
- Lansoptol (Hungary)
- Lansox (Italy)
- Lansoloc (South Africa)
- Lanton (Israel)
- Lanzor (France)
- Laprazol (Greece)
- Lanciprol (Greece)
- Limpidex (Italy)
- Monolitum (Spain)
- Ogast and OgastORO (France)
- Ogastro (Mexico)
- Prevacid (U.S. and Canada) Prevacid is a product of Takeda Pharmaceuticals.
- Prevacid 24HR (U.S.)
- pro-ulco (Spain)
- Prosogan and Prosogan FD (Indonesia)
- Refluxon (Hungary)
- SOLOX (New Zealand)
- Takepron (Japan)
- Zolt (Finland)
- Zoton (Italy, Ireland, Australia, UK)
- ZOMEL (Ireland)
Lansoprazole is also available as a generic drug in the UK, Canada, Belgium, Finland[14], France, Colombia, Italy and Mexico.[citation needed]
References
- ^ a b Mosby's Drug Consult: Lansoprazole
- ^ Teva to release Prevacid version when patent expires
- ^ "[www.prevacid24hr.com/pdfs/News%20media%20release%20-%20Prevacid24HR%20Launch%20-%20November%202009.pdf Novartis launches Prevacid 24HR over-the-counter for full 24-hour frequent heartburn treatment]" (PDF). Press release. November 12, 2009. www.prevacid24hr.com/pdfs/News%20media%20release%20-%20Prevacid24HR%20Launch%20-%20November%202009.pdf. Retrieved 2009-11-13.
- ^ "[www.prevacid24hr.com/pdfs/PackageInsert.pdf Prevacid 24HR Patient Package Insert]" (PDF). November 12, 2009. www.prevacid24hr.com/pdfs/PackageInsert.pdf. Retrieved 2009-11-13.
- ^ "[www.novartis.com/newsroom/media-releases/en/2009/1354451.shtml Novartis launches Prevacid 24HR over-the-counter for full 24-hour frequent heartburn treatment]". Press release. November 12, 2009. www.novartis.com/newsroom/media-releases/en/2009/1354451.shtml. Retrieved 2009-11-13.
- ^ http://www.patient.co.uk/showdoc/30002943/
- ^ www.mainecarepdl.org/index.pl/genpharmfiles/memos-and-mailings/pharmacy-benefit-update-summer-fall-2009.pdf
- ^ a b "Prevacid Pharmacology, Pharmacokinetics, Studies, Metabolism". RxList.com. 2007. http://www.rxlist.com/cgi/generic/lansop_cp.htm. Retrieved 2007-04-14.
- ^ "[www.prevacid24hr.com/pdfs/Prevacid24HR_Product_Fact_Sheet.pdf Prevacid 24HR Fact Sheet]" (PDF). November 12, 2009. www.prevacid24hr.com/pdfs/Prevacid24HR_Product_Fact_Sheet.pdf. Retrieved 2009-11-13.
- ^ Antimicrob Agents Chemother. 1991 September; 35(9): 1765–1771. Effects of ranitidine and sucralfate on ketoconazole bioavailability. S C Piscitelli, T F Goss, J H Wilton, D T D'Andrea, H Goldstein, and J J Schentag [1]
- ^ Yang YX, Lewis JD, Epstein S, Metz DC (December 2006). "Long-term proton pump inhibitor therapy and risk of hip fracture". JAMA 296 (24): 2947–53. doi:10.1001/jama.296.24.2947. PMID 17190895.
- ^ "Proton pump inhibitors and Clostridium difficile". Bandolier. 2003. http://www.medicine.ox.ac.uk/bandolier/booth/Pharmacy/PPIcdiff.html. Retrieved 2007-07-13.
- ^ Herzig SJ, Howell MD, Ngo LH, Marcantonio ER (May 2009). "Acid-suppressive medication use and the risk for hospital-acquired pneumonia". JAMA 301 (20): 2120–8. doi:10.1001/jama.2009.722. PMID 19470989.
- ^ http://www.terveyskirjasto.fi/terveysportti/geneerinen.substituutio?p_ryhma=0000130030
External links
- Prevacid (manufacturer's website)
- [www.prevacid24hr.com/ Prevacid 24HR] (manufacturer's website)
- Prevacid Pediatrics (manufacturer's website)
- Prevpac (manufacturer's website)